Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 8.00 · gapped above the open, then crossed back over prior close. High/low 8.05 at 8:15 am ET, 7.77 at 10:15 am ET.
Kyntra Bio, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Our revenue for the year ended December 31, 2025 primarily included $5.8 million of drug product revenue from commercial-grade active pharmaceutical ingredient ("API") or bulk drug product sales to Astellas.”
FILING10-K0001193125-26-108346cik 0000921299
“During the years ended December 31, 2025 and 2024, included in the discontinued operations, we recognized $218.6 million and $159.0 million of net product revenue from the sales to Falikang, and $8.1 million and $14.7 million of net product revenue from sales directly to distributors in one province in China, respectively.”
FILING10-K0001193125-26-108346cik 0000921299
“We currently rely, and expect to continue to rely, on third parties to scale-up, manufacture and supply roxadustat and our other product candidates for drug product in Europe and other countries, and on our partner Astellas for drug product in Japan.”
FILING10-K0001193125-26-108346cik 0000921299
“We have entered into an Evaluation Agreement with Fortis Therapeutics, Inc. ("Fortis") under which we rely, in part, on Fortis and its development partners, including University of California, San Francisco, for the continued development of FG-3246 (in conjunction with our PET biomarker).”
FILING10-K0001193125-26-108346cik 0000921299
“Shanghai SynTheAll Pharmaceutical Co., Ltd. ("WuXi STA"), our supplier of roxadustat drug substance, is also included in this legislation since it is a branch of WuXi Apptec.”
FILING10-K0001193125-26-108346cik 0000921299
“This can impact the FG-3246 program as we source the linker and payload from WuXi STA and we manufacture antibody, antibody drug conjugate drug substance and antibody drug conjugate drug product at WuXi Biologics and WuXi XDC.”
FILING10-K0001193125-26-108346cik 0000921299
“This can impact the FG-3246 program as we source the linker and payload from WuXi STA and we manufacture antibody, antibody drug conjugate drug substance and antibody drug conjugate drug product at WuXi Biologics and WuXi XDC.”
FILING10-K0001193125-26-108346cik 0000921299
“In 2020, we entered into a Master Supply Agreement with AstraZeneca under the AstraZeneca U.S./RoW Agreement (the "AstraZeneca Master Supply Agreement") to define general forecast, order, supply and payment terms for AstraZeneca to purchase roxadustat bulk drug product from Kyntra Bio in support of commercial supplies.”
FILING10-K0001193125-26-108346cik 0000921299
“We have entered into an Evaluation Agreement with Fortis Therapeutics, Inc. ("Fortis") under which we rely, in part, on Fortis and its development partners, including University of California, San Francisco, for the continued development of FG-3246 (in conjunction with our PET biomarker).”
FILING10-K0001193125-26-108346cik 0000921299
“In April 2023, we entered into an Amended and Restated Exclusive License Agreement with Eluminex ("A&R Eluminex Agreement") in order to add to the license rights to recombinant human collagen Type I (in addition to the rights to collagen Type III that were already licensed).”
FILING10-K0001193125-26-108346cik 0000921299
“As disclosed in our Current Report on Form 8‑K filed in February 20, 2025, we agreed to two holdback amounts from the consideration paid by AstraZeneca Treasury Limited (the "AZ Holdbacks") in connection with the sale of FibroGen International and its subsidiaries.”
FILING10-K0001193125-26-108346cik 0000921299
Watchlist prices, news filtered to it, and its next report on your desk.
Kyntra Bio, Inc. has 6 disclosed suppliers and 5 disclosed customers. Each one is named in an SEC filing, either Kyntra Bio, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
KYNB (Kyntra Bio, Inc.) has 6 disclosed suppliers and 5 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: AZN −1.27%, in industrials & materials.